bioRxivPharmacology & ToxicologyPreprint
Multiscale modeling of the subcutaneous administration of peptides
Abstract
With the increasing prevalence of subcutaneous administration of peptides, understanding their release and absorption is key to designing formulations with desired pharmacokinetics. Though the absorption of monoclonal anti-bodies (mAbs) has been widely explored through computational modeling, that of peptides remains poorly understood, as key features of peptide absorption, including concentration-dependent oligomerization and reversible binding with serum albumin and extracellular matrix, have not been captured. In this work, we present a first-of-its-kind approach to simulating subcutaneous administration of peptides that couples a high-fidelity tissue-level poroelastic model with a systemic compartment pharmacokinetic model. While accounting for competing binding and oligomerization tendencies of peptides, the model not only captures the process of injection but also tracks the absorption over subsequent days. We demonstrate the model using a single-dose administration of semaglutide and validate it against experimentally observed pharmacokinetic parameters. The results show the distribution of the different forms of the injected peptide throughout the body and describe the role of binding in sustaining its release. The model also reveals novel mechanisms, such as albumin-bound monomers enveloping the plume and the balance of oligomerization and binding in early stages of peptide absorption.
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Roles of Interstitial Albumin in the Subcutaneous Delivery of Therapeutic Peptides
Dávid Juriga, Anton Norberg, … Per Hansson·bioRxiv·Oct 20, 2026
- Structure-Property-Performance Engineering of Hydrogel Depots for Long-Acting Peptide Delivery
Changxin Dong, Andrea I. d’Aquino, … Eric Andrew Appel·bioRxiv·May 18, 2026
- Potential Opportunities of Modeling Bioavailability for Monoclonal Antibodies: An Overview of mAbs and the current challenges of mAb development
- The limitation of lipidation: conversion of semaglutide from once-weekly to once-monthly dosing
Eric L. Schneider, John A. Hangasky, … Daniel V. Santi·Proceedings of the National Academy of SciencesPeer-reviewed·Nov 12, 2024
- Reversible peptide self-assembly enables sustained drug delivery with tuneable pharmacokinetics
Therese W. Herling, Jiapeng Wei, … Ana L Gomes dos Santos·bioRxiv·Mar 27, 2026
- Sustained release and pharmacologic effects of human glucagon-like peptide-1 and liraglutide from polymeric microparticles.
L. P. Icart, F. G. Souza, L. M. Lima·bioRxiv·Feb 9, 2018